Precision drug service provider Dunen raises nearly CNY 100 million
The funds will be used to build a pharmaceutical services industry ecosystem.
Dunen (Chinese: 盾恩医学) recently received nearly 100 million CNY (15.38 million USD) in the strategic funding round from CCIC Capital and other domestic investors.
The results will be used to develop a precision medication clinical platform and a precision medication database. Dunen also said he plans to invest in research and product development related to pharmacogenetic testing and therapeutic medication monitoring, as well as medication guidance software based on big data and AI pharmacists.
Founded in 2017 and based in Hangzhou, Zhejiang, Dunen is the landing unit of “Precision Drug Research Center” affiliated with Yangtze Delta Region Research Institute of Tsinghua University. With a team of strong R&D capabilities, the company is committed to providing better and more reliable precision medicine solutions to medical experts and patients around the world, and promoting the development of human health.
“Dunen is currently an innovative biopharmaceutical company with great development potential. With this round of funding, we are confident to take the brand to the next level,” said Chen Zhijun, Founder of Dunen.
Shao Xiangrong, deputy secretary of the Yangtze Delta Region Research Institute of Tsinghua University, said, “We strongly endorse its presence in the pharmaceutical service industry and will continue to provide services such as recruitment talent, training and technical innovation for the company. We hope that Duneen can become the next unicorn in this segment.
“Irrational medication is one of the big challenges facing the entire industry, which can lead to mistreatment and even death. We hope Dunen will adhere to its patient-centered philosophy and constantly improve the level of pharmaceutical services,” said Professor Chen Shuqing of Zhejiang University School of Pharmacy.
Dunen’s competitors in precision medicine include Hangzhou KBM Life sciences, Huizhong Bio, Zhunce Bio, Huidu Medical and GS Medical.